M Peter Marinkovich

Biography
Dr. Marinkovich received his dermatology training at Oregon Health Sciences University, and his research training in the laboratory of Dr. Robert Burgeson, who discovered type VII collagen. Dr. Marinkovich's early work led to the characterization of several key basement membrane components involved in epidermolysis bullosa, including laminin-332 and laminin-311. He later joined the faculty at Stanford University and served as an attending in the National EB Registry at Stanford University. He currently directs the Stanford Blistering Disease Clinic. Dr. Marinkovich’s laboratory has had a longstanding focus on the development of molecular therapy for various subtypes of epidermolysis bullosa.

---

Talk
Emerging Gene Therapies for Epidermolysis Bullosa
Dystrophic epidermolysis bullosa is a skin fragility disorder characterized by blistering in response to minor trauma. Advances in our understanding of epidermolysis bullosa pathophysiology and gene therapy vectors have led to successive advancements in dystrophic epidermolysis bullosa molecular correction, demonstrating that gene therapy for epidermolysis bullosa is safe and effective.